Skip to search formSkip to main contentSkip to account menu

boceprevir

Known as: 3-Azabicyclo(3.1.0)hexane-2-carboxamide, N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-((2S)-2-((((1,1- dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6- dimethyl-, (1R,2S,5S)-, N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide 
An orally bioavailable, synthetic tripeptide inhibitor of the nonstructural protein 3 and 4A complex (NS3/NS4A), with potential activity against… 
National Institutes of Health

Related topics

Related topics

7 relations
HCV NS3/4A Protease Inhibitors [MoA]Hepatitis Canalogs & derivativesboceprevir 200 MG Oral Capsule [Victrelis]

Broader (1)

Proline

Narrower (2)

SCH-503034Victrelis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy.
Highly Cited
2013
Highly Cited
2013
Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.
Highly Cited
2013
Highly Cited
2013
Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible?
Highly Cited
2013
Highly Cited
2013
Discovery of Hepatitis C Virus NS3 Helicase Inhibitors by a Multiplexed, High‐Throughput Helicase Activity Assay Based on Graphene Oxide†
A GO‐to solution: A simple graphene oxide (GO)‐based assay to screen for selective inhibitors of a hepatitis C virus (HCV… 
Review
2013
Review
2013
Management of anemia induced by triple therapy in patients with chronic hepatitis C: challenges, opportunities and recommendations.
Review
2012
Review
2012
New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials
Introduction:  Hepatitis C virus (HCV) affects approximately 3% of the world population. The current standard of care for… 
Highly Cited
2011
Highly Cited
2011
New Merck and Vertex drugs raise standard of care in hepatitis C
Review
2011
Review
2011
Resistance to anti-HCV protease inhibitors.
Review
2009
Review
2009
Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection.
Boceprevir is an HCV NS3 (non-structural protein 3) serine protease inhibitor being developed by Schering-Plough Corp as a… 
Highly Cited
2008
Highly Cited
2008
Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)
ABSTRACT HCV-796 is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase, and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)